X0202 SCHEDULE 13G/A 0001104659-25-112821 0001674546 XXXXXXXX LIVE 1 Common Stock 03/31/2026 0000744218 Celldex Therapeutics, Inc. 15117B202 Perryville III Building 53 Frontage Road, Suite 220 Hampton NJ 08827 Rule 13d-1(b) Bellevue Group AG a V8 0.00 1200000.00 0.00 1200000.00 1200000.00 N 1.5 HC CO The percentage set forth in Row 11 is calculated based on 78,492,072 shares of Common Stock deemed outstanding. This Amendment No. 1 constitutes an exit filing for the Reporting Person as the Reporting Person owns less than five percent (5%) of the common shares of the Issuer. Bellevue Asset Management AG a V8 0.00 1200000.00 0.00 1200000.00 1200000.00 N 1.5 CO The percentage set forth in Row 11 is calculated based on 78,492,072 shares of Common Stock deemed outstanding. This Amendment No. 1 constitutes an exit filing for the Reporting Person as the Reporting Person owns less than five percent (5%) of the common shares of the Issuer. Celldex Therapeutics, Inc. Perryville III Building, 53 Frontage Road, Suite 220, Hampton, NJ 08827 Bellevue Group AG ("Bellevue") on behalf of its wholly-owned subsidiary, Bellevue Asset Management AG ("BAM AG") Bellevue: Theaterstrasse 12, Zurich, Switzerland, CH-8001 BAM AG: Theaterstrasse 12, Zurich, Switzerland, CH-8001 Bellevue: Switzerland BAM AG: Switzerland N FI Swiss Financial Market Supervisory Authority (FINMA) 1,200,000 1.5% 0 1,200,000 0 1,200,000 N Y Y N This statement is filed jointly by Bellevue and BAM AG. BAM AG is a wholly-owned subsidiary of Bellevue. Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Bellevue Group AG /s/ Stefano Montalbano 05/11/2026 /s/ Christoph Eisenring 05/11/2026 Bellevue Asset Management AG /s/ Christoph Eisenring 05/11/2026 /s/ Ivo Betschart 05/11/2026